Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbaclofen Extension Study in Fragile X Syndrome
NCT01555333Phase 3Terminated
- Sponsor
- Seaside Therapeutics
- Start
- Nov 2011
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of arbaclofen in Fragile X syndrome (FXS), sponsored by Seaside Therapeutics. Started Nov 2011; status: terminated.
02
Drugs
arbaclofen
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT01555333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01555333.